news
Medicenna’s MDNA11 a promising alternative to checkpoint inhibitors
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
List view / Grid view
Immuno-oncology therapeutics
news
STING-activating drugs could customise cancer treatments
An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
news
Stem-like T cells could improve immunotherapy treatments
Targeting stem-like T cells within certain lymph nodes could improve the number of cancer patients that respond to immunotherapy treatments.
news
High-intensity focused ultrasound therapy moves closer to the clinic
Researchers are investigating how high-intensity focused ultrasound (HIFU) can work on a cellular level to treat a range of cancers.
news
Triple drug combination shows promise for pancreatic cancer treatment
MIT researchers have shown that a combination of three drugs can eliminate pancreatic tumours in mice, possibly leading to new therapies.
news
Inhibiting PIP4K enzymes could help immune system fight cancer
Researchers identified a potential therapeutic involving the inhibition of PIP4K enzymes which could enable the immune system to destroy tumour cells.
news
Personalised organoid models may improve immunotherapy treatment
Researchers have used patient-specific tumour organoid models to improve immunotherapy treatments for appendiceal cancer.
article
Immunosurveillance and the importance of CD4 T cells in developing cancer vaccines
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
news
NIK could be key to enhancing the effects of immunotherapy
Immunology study shows that NF-kappa B-inducing kinase (NIK) is critical to T cell metabolism and the antitumour immune response.
news
Studies in mice reveal link between obesity and tumour growth
New research has provided a metabolic atlas for insights into obesity and tumours' ability to hide from the immune system.
news
Cancer-killing virus could improve precision medicine
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
article
The next generation of cancer immunotherapies: re-exploring the IL-2 pathway
In this article, Dr Bruce Dezube explains why new cancer immunotherapy drugs that utilise the IL-2 pathway with lower side effects could offer more benefits compared to high-dose IL-2 treatment.
news
iPSC-derived natural killer cells show promise against leukaemia in mice
By deleting the CISH gene from natural killer cells made from iPSCs, researchers say they have effectively treated leukaemia in vivo and in vitro.
article
What immuno-oncology research can tell us about COVID-19
Dr Jing Watnick discusses how lessons learnt from cancer immunotherapy treatments could be applied to the development of COVID-19 therapies.
article
Triplet immuno-oncology drug combinations – the future of treating multiple cancer
The oncology market is saturated with new drugs that target the immune system, however, these only target part of the problem caused by cancer’s ability to hide from the immune system. Miguel Ferreira discusses why emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with…
